You are here

Article Text

Article menu

Download PDFPDF

XML
Neurology
Cohort profile
Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration
  1. Jan F Scheitz1,
  2. Henrik Gensicke2,
  3. Sanne M Zinkstok3,
  4. Sami Curtze4,5,
  5. Marcel Arnold6,
  6. Christian Hametner7,
  7. Alessandro Pezzini8,
  8. Guillaume Turc9,
  9. Andrea Zini10,
  10. Visnja Padjen11,
  11. Susanne Wegener12,
  12. Annika Nordanstig13,
  13. Lars Kellert14,
  14. Georg Kägi15,
  15. Yannick Bejot16,
  16. Patrik Michel17,
  17. Didier Leys18,
  18. Christian H Nolte1,
  19. Paul J Nederkoorn3,
  20. Stefan T Engelter2,19
  21. on behalf of the TRISP collaboration
    1. 1 Department of Neurology and Center for Stroke Research, Charité-Universitätsmedizin Berlin, Berlin, Germany
    2. 2 Department of Neurology and Stroke Center, University of Basel and University Hospital Basel, Basel, Switzerland
    3. 3 Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands
    4. 4 Department of Neurology, Helsinki University Hospital, Helsinki, Finland
    5. 5 Department of Neurological Sciences, University of Helsinki, Helsinki, Finland
    6. 6 Department of Neurology, lnselspital, Bern University Hospital, University of Bern, Bern, Switzerland
    7. 7 Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany
    8. 8 Department of Clinical and Experimental Sciences, Neurology Clinic, University of Brescia, Brescia, Italy
    9. 9 Université Paris Descartes Sorbonne Paris Cité, Centre Hospitalier Sainte-Anne, Paris, France
    10. 10 Stroke Unit, Department of Neuroscience, Nuovo Ospedale Civile S. Agostino-Estense, University Hospital, Modena, Italy
    11. 11 Neurology Clinic, Clinical Centre of Serbia, Belgrad, Serbia
    12. 12 Department of Neurology, University of Zürich, Zürich, Switzerland
    13. 13 Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
    14. 14 Department of Neurology, Klinikum der Universität München, Ludwig-Maximilians University, München, Germany
    15. 15 Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland
    16. 16 Dijon Stroke Registry, EA4184, University Hospital and Medical School of Dijon, University of Burgundy, Dijon, France
    17. 17 Department of Neurology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    18. 18 Department of Neurology, University of Lille, Lille, France
    19. 19 Neurorehabilitation Unit, University of Basel and University Center for Medicine of Aging and Rehabilitation, Felix Platter Hospital, Basel, Switzerland
    1. Correspondence to Professor Stefan T Engelter; Stefan.Engelter{at}usb.ch

    Abstract

    Purpose The ThRombolysis in Ischemic Stroke Patients (TRISP) collaboration aims to address clinically relevant questions about safety and outcomes of intravenous thrombolysis (IVT) and endovascular thrombectomy. The findings can provide observational information on treatment of patients derived from everyday clinical practice.

    Participants TRISP is an open, investigator-driven collaborative research initiative of European stroke centres with expertise in treatment with revascularisation therapies and maintenance of hospital-based registries. All participating centres made a commitment to prospectively collect data on consecutive patients with stroke treated with IVT using standardised definitions of variables and outcomes, to assure accuracy and completeness of the data and to adapt their local databases to answer novel research questions.

    Findings to date Currently, TRISP comprises 18 centres and registers >10 000 IVT-treated patients. Prior TRISP projects provided evidence on the safety and functional outcome in relevant subgroups of patients who were excluded, under-represented or not specifically addressed in randomised controlled trials (ie, pre-existing disability, cervical artery dissections, stroke mimics, prior statin use), demonstrated deficits in organisation of acute stroke care (ie, IVT during non-working hours, effects of onset-to-door time on onset-to-needle time), evaluated the association between laboratory findings on outcome after IVT and served to develop risk estimation tools for prediction of haemorrhagic complications and functional outcome after IVT.

    Future plans Further TRISP projects to increase knowledge of the effect and safety of revascularisation therapies in acute stroke are ongoing. TRISP welcomes participation and project proposals of further centres fulfilling the outlined requirements. In the future, TRISP will be extended to include patients undergoing endovascular thrombectomy.

    • stroke
    • thrombolysis
    • registry
    • functional outcome
    • thrombectomy
    • revascularization

    This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

    https://doi.org/10.1136/bmjopen-2018-023265

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      View Full Text

      Footnotes

      • Contributors All authors conceived the study and developed the protocol. JFS wrote the first draft. JFS, HG, SMZ, SC, MA, CH, AP, GT, AZ, VP, SW, AN, LK, GK, YB, PM, DL, CHN, PJN, STE critically revised the manuscript for important intellectual content, were involved in study concept and design, will be involved in acquisition of data and approved the final version of the manuscript. All contributors listed in the supplemental material approved submission of the manuscript.

      • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

      • Competing interests JFS has received speaker honoraria from W L Gore & Associates GmbH and travel support from Bayer and Boehringer-Ingelheim; HG has received research support from the Swiss National Science Foundation; AZ has received funding for speaker honoraria and consulting fees from Boehringer-Ingelheim and Medtronic-Covidien and consulting fees from Nestec; GK received grants from Swiss Parkinson Association, Swiss Heart Association, Swiss National Science Foundation and served on advisory boards for Boehringer-Ingelheim, Bayer, Daiichi Sankyo (Schweiz) AG, Zambon, Nestle, GE Healthcare within the last two years; YB received honoraria or consulting fees from AstraZeneca France, Daiichi-Sankyo, BMS-Pfizer, Covidiem, Bayer and MSD France; PM received research grants from the Swiss National Science Foundation, the Swiss Heart Foundation; speaker fees from Boehringer-Ingelheim, Bayer, Covidien and Stryker; honoraria from scientific advisory boards from Boehringer-Ingelheim, Bayer, Pfizer, Amgen; consulting fees from Pierre-Fabre and Astra-Zeneca; and travel support from Boehringer-Ingelheim and Bayer. All this support is received by the institution (CHUV) and is used for stroke education and research; DL participated during the last 5 years to 1 advisory boards, symposia or trials sponsored by Sanofi Aventis, BMS, Astrazeneca, Boeringher-Ingelheim, Servier, Ebewe, CoLucid Pharm, Brainsgate, Photothera, Lundbeck, GSK, Bayer, Pfizer et Allergan (honorarium paid to Adrinord or research account of the hospital) and was an associated editor of the Journal of neurology, neurosurgery and psychiatry 2004-2010 (personal financial compensation); CHN has received funding for travel or speaker honoraria from Bayer, Boehringer-Ingelheim, Takeda, and BMS/Pfizer; PJN has received consulting fees from Boehringer-Ingelheim; STE has received funding for travel or speaker honoraria from Bayer and Boehringer-Ingelheim, he has served on scientific advisory boards for Bayer, Boehringer-Ingelheim, BMS/Pfizer and Covidien and on the editorial board of Stroke. He has received an educational grant from Pfizer and research support from the Science Funds (Wissenschaftsfonds) of the University Hospital Basel, the University Basel, the Swiss Heart Foundation and the Swiss National Science Foundation.

      • Patient consent Not required.

      • Provenance and peer review Not commissioned; externally peer reviewed.

      • Data sharing statement Data sharing will be restricted to non-commercial and academic purposes only. Data ownership remains at the center that originally obtained the data. The centers will have to give permission for re-use of the data. Data inquires or further suggestions for analyses/participation in TRISP can be made to the corresponding author (STE) or PJN.